Zydus Lifesciences share price advanced over 5 percent in trade today after the company announced an agreement with US healthcare firm CVS Caremark to add its diabetes combination products to its template formulary. Zydus Lifesciences reacted sharply to the development in Tuesday's trade with the counter rising 5.23 percent to an intraday high of Rs 1,011.75 per share on the NSE.
Source: FlipItMoney
Ad
Ad